Moleculin Biotech, Inc.

Hello, and welcome to the Moleculin Biotech inaugural quarterly update conference call and webcast. As a brief reminder, all participants are currently in a listen-only mode. If anyone requires operator assistance during the event, please press star zero on your telephone keypad. Following the presentation, there will be a question and answer session. Note that this webcast is being recorded at the company's request, and a replay will be made available on the company's website following the end of the event. At this time, I'd like to remind our listeners that remarks made during this webcast may state management's intentions, beliefs, expectations, or future projections. These are forward-looking statements and involve risk and uncertainties. Forward-looking statements on this call are made pursuant to the safe harbor provisions of the federal securities laws and are based on the election's current expectations and actual results differ materially. As a result, you should not place undue reliance on any forward-looking statements. Some of the factors that could cause actual results to differ materially from these contemplated by such forward-looking statements are discussed in the periodic reports, molecular files with the Securities and Exchange Commission. These documents are available on the investor section of the company's website and on the Securities and Exchange Commission's website. We encourage you to review these documents carefully. Additionally, certain information contained in this webcast relates to or is based on studies, publications, surveys, and other data obtained from third-party sources and the company's own estimates and research. While the company believes these third party sources to be reliable as the date of this presentation, it's not independently verified and makes no representation as to the adequacy, fairness, accuracy, or completeness of any of the independent sources as verified, any information obtained from third party sources. Joining us on today's call from Electrical Leadership Team are Walter Klemp, Chairman and Chief Executive Officer, and Jonathan Foster, Executive Vice President and Chief Financial Officer. I would now like to turn the conference over to Walter Klemp. Please go ahead.

Welcome, everyone. Today marks an important moment for the company as we kick off our inaugural earnings call. We're proud of the fact that our clinical trials have been progressing according to plan and we've arrived at a point where our vision and our hope for our pipeline are now being validated by significant data. And I'm pleased to say that this progress and these data are beginning to drive a noteworthy evolution of the company. Three Phase 1-2 clinical trials are now underway for anamycin, and we just announced a follow-up report from an independent expert that continues to document the complete absence of cardiotoxicity for what we believe is a remarkable anthracycline. In addition to the data we've recently reported, we expect several additional milestones, trial progress, and data points before this year is over. And importantly, we believe that we are in a great cash position to continue delivering value inflection points and milestones beyond mid 2024. In our view, 2022 really has been a transformation year for molecular. It's allowed us to gain critical mass across our entire pipeline. For anamycin, we not only completed the phase one portion of our STS lung mets trial in the U.S., but we also kicked off two additional phase one, two trials, one in STS lung mets using an alternate dosing regimen and one combining anamycin with cytarabine in relapsed refractory AML. We also had additional preclinical data from our sponsored research at MD Anderson Cancer Center suggesting that the next additional indication for anamycin might well be pancreatic cancer because of our unique ability to accumulate in the pancreas where other anthracyclines simply can't. Beyond anamycin, our anti-metabolite portfolio really came into its own this year with the startup and completion of a phase one trial of WP 1122 in healthy volunteers, where we set an MTD or maximum tolerated dose to be utilized in possible future trials. We see the possibility for these trials to be in both oncology and virology. And our intent is to tackle the bulk of this with external funding. In fact, Our 1122 portfolio has now expanded into an IND clearance for GBM, and most recently, with NIH funding being awarded to the WP1096 analog as a possible therapy for arena viruses. And finally, our STAT3 inhibitor portfolio, led by WP1066, is now nearing completion of its first phase one study in pediatrics. And that sets the stage for its combination with radiation in a range of brain tumor indications. Now, in order to fully appreciate the opportunity that adamycin represents, I think it's helpful to understand just how different it is from currently prescribed anthracyclines like doxorubicin. Anthracyclines are a cornerstone chemotherapy for hundreds of thousands of patients every year. but their use has been hampered for decades because of their inherent cardiotoxicity and their inability to reach certain important targets. But anamycin was designed to be non-cardiotoxic, and we just received another report from an independent cardiology expert assessing results from two of our trials covering an additional 18 subjects. Like the prior assessment, this one concluded that there was no cardiotoxicity with anamycin. And this brings us to a total of 42 subjects in our anamycin trials where no evidence of cardiotoxicity has been identified. And again, this is by an independent expert cardiologist. And all the preclinical data supports our expectation that anamycin may be able to outperform doxorubicin in terms of efficacy in many tumors, in part because we've shown in animal models that it's capable of accumulating in certain targeted organs at much higher concentrations. In fact, its ability to concentrate in the lungs at 30 times the level of doxorubicin in preclinical studies is what led to the successful conclusion of a phase 1B study of anamycin in patients with soft tissue sarcoma lung mets. And we're now into the phase 2 portion of that trial. We believe that there is a very significant unmet need here, and we're already showing activity in patients who stopped responding to doxorubicin, which is the standard of care. That U.S. study is now being flanked by an investigator-led study in the EU in the same patient population, but using a weekly dosing regimen. Preclinical data from MD Anderson showed that this dosing regimen was more effective than the standard monthly dosing that has been historically universal for anthracyclines, and this led to the EU grant funding of this trial. In the case of acute myeloid leukemia, or AML, we successfully concluded a phase one study demonstrating once again that anamycin is safe. We set a recommended phase two dose, And we showed a 60% overall response rate in patients in the last cohort. And these are patients who were relapsed or refractory after multiple previous combination therapies. Here again, our ongoing research collaboration with MD Anderson demonstrated that when you combine anamycin with cytarabine, a drug commonly used with AML patients, It's 68% more effective than single agent anamycin in a very aggressive AML mouse model. So we've now started up a phase one, two in this indication with the combination. And this is what led to our decision to conclude the single agent study after setting the RP2D and moving directly into a combination trial. This way we continue advancing anamycin, but we also conserve our cash runway. Switching for a moment to WP 1122 and our anti-metabolite technologies, the story here has gotten more interesting. What started out early in the pandemic as a race to provide a therapeutic option for COVID-19 has now evolved into what we believe is a broader opportunity. We just completed a phase one trial in healthy volunteers, demonstrating that 1122 is safe and setting an MTD. And even though the COVID opportunity itself is cooling off as the pandemic winds down, this trial has now put us in a great position to exploit the USIND approval we have in GBM, and we're in discussions already with potential collaborators for that opportunity. At the same time, however, our COVID research efforts uncovered an analog in the WP1122 portfolio that we call WP1096. and it's showing some very interesting antiviral potential in preclinical studies. In fact, based on the in vitro data generated in our work with UTMB Galveston and the CDC-funded Galveston National Labs, the NIH is now providing funding for an animal study of 1096 in an arena virus. Now, this in vitro data points to strong activity against some of the worst viruses out there, including Ebola, Marburg, Zika, and even HIV. So we plan to continue advancing the 1122 portfolio, and we intend to do most of this with external non-dilutive funding in both oncology and virology. Now, while we've achieved a lot this year, I believe this is just the beginning of our transformation, and we're poised to significantly build on this momentum with more important news to come yet this year, and into 2023. The U.S. clinical trial of antimycin in STS lung mets continues to move quickly, so we should have interim Phase II data to report in Q1 of 2023. Also, both European trials, that's one in STS and one in AML, should show Phase I progress this year that we expect will lead to Phase II activity and data next year. And as I mentioned, the NIH has started funding an animal trial of WP1096 in the arena virus space, and we appear to be on track to see results from that trial this year as well. So now let me invite our EVP CFO, Jonathan Foster, to give his take on our financial situation before we wrap this up. John?

Thanks, Wally. One of the many differences molecular has over other small biotechs we believe is our strong cash position. Continue to focus on a minimum cash burn rate while advancing our portfolio in multiple trials and multiple indications with both internal and external funds. We are focused on outsourcing where we can and with a minimum workforce. And this helps us maintain this lengthy cash runway. Regarding this quarter, R&D expense of just shy of $15 million outpaces last year's expense, mirroring the increase in clinical activity Wally just mentioned. G&A expense of $8.7 million was higher than prior years due to increased legal costs. The company ended the quarter with over $50 million in cash on hand. We believe this is sufficient to fund our operations beyond mid-2024 and fund the company-led trials Wally has just described and provide time for us to deliver very important human data. I strongly believe this strength along with our multiple shots on gold sets us apart from other small biotechs. Wally?